The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Coronary interventions

Five-year safety and performance data of a novel third-generation novolimus-eluting bioresorbable scaffold in single de novo lesions

EuroIntervention 2019;15:685-687. DOI: 10.4244/EIJ-D-18-00292

1. ZNA Middelheim, Antwerp, Belgium; 2. Instituto Dante Pazzanese, São Paulo, Brazil; 3. Universitäres Herz- und Gefäβzentrum Hamburg, Hamburg, Germany; 4. Mercy Hospital, Auckland, New Zealand; 5. Aarhus University Hospital, Aarhus, Denmark; 6. University Hospital in Krakow, Department of Interventional Cardiology, Krakow, Poland; 7. Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Medizinische Klinik für Kardiologie, Berlin, Germany; 8. ICT/Instituto Do Coracao Do Triangulo Mineiro, Uberlandia, Brazil; 9. Cardiovascular Research Center, São Paulo, Brazil; 10. Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands


Bioresorbable scaffolds (BRS) were designed as an alternative to metallic stents with the goal of complete resorption to allow vascular remodelling and to decrease late clinical events associated with permanent implants1.

The DESolve® scaffold (Elixir Medical Corporation, Milpitas, CA, USA) is a next-generation scaffold with an early biodegradation and bioresorption profile that has demonstrated positive vascular remodelling at six months and favourable clinical outcomes2,3. The device is comprised of poly-L-lactic acid (PLLA) coated with a matrix of novolimus and a polylactide-based polymer. The strut thickness is 150 µm. We report the five-year clinical results with 18...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Impact of adjunctive use of guide extension catheter on midterm outcome of drug-coated balloon angioplasty